Revive Therapeutics (TSXV:
$RVV.V) (OTCQB: $RVVTF) Announces Update on Development of Datametrex
Artificial Intelligence Component in #Blockchain Enabled Patient-Focused
Program for Medical #Cannabis Sector
TORONTO, ONTARIO - December 4, 2017
(Investorideas.com Newswire) Revive Therapeutics Ltd. ("Revive" or
the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on
the research, development and commercialization of novel therapies and
technologies for the medical cannabis and pharmaceutical sectors, today
announced an update on the development of the Artificial Intelligence
("AI") component for Revive's proposed proprietary patient-focused
program dedicated to the medical cannabis industry enabled by Blockchain
technology. This update follows Datametrex AI Limited ("Datametrex")
(TSX VENTURE:DM)(FRANKFURT:D4G) recent announcement of Datametrex's wholly
owned subsidiary, Nexalogy Environics Inc. ("Nexalogy"), entered into
a license and development agreement with Revive.
Revive is aiming to incorporate Nexalogy's
proprietary social data discovery solution, NexaIntelligence, to unlock the
value of data related to medical cannabis collected from social media networks
and internet environments such as discussion forums, blogs and news sites.
Through data mining and analytics, information aggregated from independent
sources on the internet will aim to provide authentic insights and uses of
cannabis on a variety of medical conditions. With its unique, easy-to-understand
visuals in a highly functional interface, NexaIntelligence, is able to conduct
a deep analysis of the ever-growing volume of online data of medical cannabis
and catch the valuable signals that lead to strategic insights and actionable
intelligence.
"We are very excited about Nexalogy's
NexaIntelligence social data software solution as it provides us with a
proprietary data collection strategy and enables us to unlock the value of
information, by artificial intelligence, currently being generated in numerous
independent social networks and environments on the internet," said Fabio
Chianelli, President of Revive. "We are focused on building a proprietary
patient-centered platform dedicated to the medical cannabis industry that will
leverage the privacy, security, and information sharing features of blockchain
and the data mining, predictive and machine learning features of AI with the
aim to engage, acquire, retain, and support medical cannabis patients. The AI
component will provide insights, analytics and recommendations that may offer
significant value to licensed producers of cannabis, healthcare professionals,
and clinical researchers."
Andrew Ryu, Chairman and CEO of Datametrex added,
"We are very encouraged to see our AI component provide such relevancy to
Revive and the cannabis sector. This is an explosive area and we will be
delivering vital data around patients."
About Datametrex AI Limited
Datametrex (TSX VENTURE:DM)(FRANKFURT:D4G) is
focused on the collection of retail sales data, providing government agencies
and Fortune 500 corporations with artificial intelligence technology and
implementing blockchain solutions for secure data transfers. The company is
planning on integrating the DataTap environment to decentralized blockchains to
further authenticate and validate the data collected. To learn more about
Datametrex, visit: www.datametrex.com.
About Nexalogy
Nexalogy is a wholly-owned subsidiary of Datametrex
AI Limited. Nexalogy AI solutions unlock valuable insights from social media
data. Through its proprietary semantic clustering algorithms, it provides
insights and analysis that are not available through traditional business
intelligence technology. This technology makes data more relevant and is the
missing link in providing actionable social media intelligence to governments
and organizations all over the world. To learn more about Nexalogy,
visit: www.nexalogy.com.
About Revive Therapeutics Ltd.
Revive Therapeutics Ltd. (TSX VENTURE:RVV)
(OTCQB:RVVTF) is focused on the research, development and commercialization of
novel therapies and technologies for the medical cannabis and pharmaceutical
sectors. Additional information on Revive is available at www.ReviveThera.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Neither the TSX-V nor its Regulation Services
Provider (as that term is defined in the policies of the TSX-V) accepts
responsibility for the adequacy or accuracy of this release.
This news release includes certain information and
statements about management's view of future events, expectations, plans and
prospects that constitute "forward-looking information" that involves
known and unknown risks and uncertainties, which are not comprised of
historical facts, and most of which are beyond the control of Revive.
Forward-looking statements include estimates and statements that describe
Revive's future plans, objectives or goals, including words to the effect that
Revive or its management expects a stated condition or result to occur.
Forward-looking statements may be identified by such terms as
"believes", "anticipates", "intends",
"expects", "estimates", "may", "could",
"would", "will", or "plan", and similar
expressions. Specifically, forward-looking statements in this news release
include, without limitation, statements regarding: the granting of a patent for
Bucillamine for the treatment of gout; the potential efficacy and commercial
viability of Bucillamine for treatment of gout and Bucillamine for the
treatment of Cystinuria; expansion of the Bucillamine clinical testing program;
the Company's drug research and development, and commercialization plans; the
Company's research, development and commercialization plans for plant-based
therapies, including cannabinoid and its delivery technology; the timing of
operations; the Company's research and development, and commercialization plans
for blockchain and artificial intelligence; and estimates of market conditions.
These statements involve known and unknown risks, uncertainties, and other
factors that may cause actual results or events, performance, or achievements
of Revive to differ materially from those anticipated or implied in such
forward-looking statements. Since forward-looking statements are based on
assumptions and address future events and conditions, by their very nature they
involve inherent risks and uncertainties. The Company believes that the
expectations reflected in these forward-looking statements are reasonable, but
there can be no assurance that actual results will meet management's
expectations. In formulating the forward-looking statements contained herein,
management has assumed: that business and economic conditions affecting Revive
will continue substantially in the ordinary course and will be favourable to
Revive; that clinical testing results will justify commercialization of the
Company's drug candidates; that Revive will be able to obtain all requisite
regulatory approvals to commercialize its drug candidates; that such approvals
will be received on a timely basis; and, that Revive will be able to find
suitable partners for development and commercialization of its drug repurposing
candidates on favourable terms. Although these assumptions were considered
reasonable by management at the time of preparation, they may prove to be
incorrect and no assurance can be given that such events will occur in the
disclosed time frames or at all.
Factors that may cause actual results to differ
materially from those anticipated by these forward-looking statements include:
uncertainties associated with obtaining regulatory approval to perform clinical
trials and market products; the need to establish additional corporate
collaborations, distribution or licensing arrangements; the Company's ability
to raise additional capital if and when necessary; intellectual property
disputes; increased competition from pharmaceutical and biotechnology
companies; changes in equity markets, inflation, and changes in exchange rates;
and other factors as described in detail in Revive's Management's Discussion
& Analysis for the period ended June 30, 2017 and Revive's other public
filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks
and uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in their
entirety by this cautionary statement. Except as required by law, Revive
disclaims any intention and assumes no obligation to update or revise any
forward-looking statements to reflect actual results, whether as a result of
new information, future events, changes in assumptions, changes in factors
affecting such forward-looking statements or otherwise.
Contact Information
Revive Therapeutics Ltd.
Craig Leon
Chief Executive Officer
(416) 272-5525
craig@revivethera.com
www.revivethera.com
Marijuana / Hemp Stocks
This news is
published on the Investorideas.com Newswire - a global digital news source for
investors and business leaders
Disclaimer/Disclosure: Investorideas.com
is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by copyright
laws other than syndication rights. Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional
info regarding BC Residents and global Investors: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
